Inventor · disambiguated record

Zhuoxiao Cao

Also filed as: CAO ZHUOXIAO

6 granted patents·32 pending applications·1 citations·filing 2017–2025

69Inventor score

Technology areasC07K A61K C12N G01N A61P

Files withJIANGSU HENGRUI MEDICINE CO9 SHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD8 SIMCERE ZAIMING PHARMACEUTICAL CO LTD6 HAINAN SIMCERE PHARMACEUTICAL CO LTD3 HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO LTD3

Top patents by PatentIndex Score

38 records

0177US12319725B2IL-2 mutant and application thereofHAINAN SIMCERE PHARMACEUTICAL CO LTD·Filed 2024·Granted Jun 3, 2025·0 cites·16 claims
0275US2025382343A1Il-2 Mutants And Uses ThereofHAINAN SIMCERE PHARMACEUTICAL CO LTD·Filed 2025·Application pending·0 cites
0373US11345753B2TIM-3 antibody, antigen binding fragment thereof, and medicinal uses thereofJIANGSU HENGRUI MEDICINE CO·Filed 2018·Granted May 31, 2022·1 cites·18 claims
0472US2024209051A1Il-2 Mutant And Application ThereofHAINAN SIMCERE PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
0569US11981733B2LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereofJIANGSU HENGRUI MEDICINE CO·Filed 2021·Granted May 14, 2024·0 cites·20 claims
0665US12421286B2Il-2 mutant and application thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2021·Granted Sep 23, 2025·0 cites·14 claims
0762US11155617B2LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereofJIANGSU HENGRUI MEDICINE CO·Filed 2017·Granted Oct 26, 2021·0 cites·21 claims
0859US2025353907A1Cd19-targeting chimeric antigen receptor and use thereofSHANGHAI SIMNOVA BIOTECHNOLOGY CO LTD·Filed 2023·Application pending·0 cites
0959US2025304717A1Camptothecin derivative and ligand-drug conjugateHAINAN SIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
1056US2025213694A1Enhanced chimeric antigen receptor and use thereofSHANGHAI SIMNOVA BIOTECHNOLOGY CO LTD·Filed 2023·Application pending·0 cites
1154US2022153853A1Bispecific proteinJIANGSU HENGRUI MEDICINE CO·Filed 2019·Application pending·0 cites
1253US11512129B2TIGIT antibody, antigen-binding fragment thereof, and medical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2018·Granted Nov 29, 2022·0 cites·19 claims
1353US2025009847A1Il-15 mutant fusion protein pharmaceutical compositionSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
1451US2024343803A1Anti-Pvrig/Anti-Tigit Bispecific Antibodies And Applications ThereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
1551US2024124575A1Human cd33 antibody and use thereofSIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
1650US2025075006A1Anti-gucy2c nano-antibody and application thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
1750US2024307415A1Steroid compound, and pharmaceutical composition thereof and use thereofJIANGSU SIMCERE PHARM CO LTD·Filed 2022·Application pending·0 cites
1850US2025297021A1Bcma antibody and use thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO NO 1·Filed 2022·Application pending·0 cites
1949US2024343811A1Cd16 antibody and use thereofSHANDONG SIMCERE BIOPHARMACUTICAL CO LTD·Filed 2022·Application pending·0 cites
2049US2025297030A1Anti-muc17 nanobody and use thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
2149US2025042994A1Cd19 antibody and application thereofHAINAN SIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
2249US2025145705A1Gprc5d antibody and application thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
2348US2022220218A1Anti-cd73 antibody, antigen-binding fragment thereof and application thereofJIANGSU HENGRUI MEDICINE CO·Filed 2019·Application pending·0 cites
2448US2021261663A1Anti-tim3 antibody pharmaceutical composition and use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2019·Application pending·0 cites
2548US2025136687A1Anti-human cd3 antibody and use thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
2647US2024084003A1Anti-human cd22 monoclonal antibodies and use thereofSIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
2747US2025179172A1Cd5 antibody and use thereofHAINAN SIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
2847US2024109974A1Humanized antibody against tnfr2 and use thereofJIANGSU SIMCERE PHARM CO LTD·Filed 2022·Application pending·0 cites
2946US2023416360A1Anti-cd22 nano antibody and use thereofSIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
3046US2025250357A1Anti-msln antibody and application thereofNANJING ZAIMING PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
3146US2025026844A1Anti-bcma nanobody and use thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
3245US2020347130A1CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use ThereofJIANGSU HENGRUI MEDICINE CO·Filed 2018·Application pending·0 cites
3345US2022017618A1Use of tim-3 antibody in preparation of medicines for treating tumorsJIANGSU HENGRUI MEDICINE CO·Filed 2019·Application pending·0 cites
3444US2023192797A1Human il-15 mutant and uses thereofJIANGSU SIMCERE PHARM CO LTD·Filed 2021·Application pending·0 cites
3543US2024076403A1Her2 antibody and application thereofSIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
3641US2024124563A1Anti-Human MSLN Antibody And Application ThereofNANJING ZAIMING PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
3740US2024052055A1Gpc3 antibody and application thereofSIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
3840US2024101686A1Anti-egfr nanobody and use thereofSIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites

Join the waitlist — get patent alerts

Get an alert when Zhuoxiao Cao files or is granted a new patent.

We store only your email — no account needed. See our privacy policy.

Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →